Work for Oyster Point Pharma, Inc.?

Claim Your Profile

Oyster Point Pharma, Inc. Logo Image

Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report and Form 10K

Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc. has reached its limit for free report views.

About Oyster Point Pharma, Inc.

11-50 Employees
Based in Princeton, New Jersey

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 nasal spray’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit (LFU).

Ticker:
OYST
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol